HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 275, Issue 42, 32879-32887, October 20, 2000

This Article Abstract Full Text (PDF) All Versions of this Article: 275/42/32879    most recent M005609200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Csordás, G. Articles by Iozzo, R. V. Search for Related Content PubMed PubMed Citation Articles by Csordás, G. Articles by Iozzo, R. V. Social Bookmarking                      What's this?

Sustained Down-regulation of the Epidermal Growth Factor Receptor by Decorin

A MECHANISM FOR CONTROLLING TUMOR GROWTH IN VIVO^*

György Csordás^§, Manoranjan Santra^§, Charles C. Reed, Inge Eichstetter, David J. McQuillan^¶, Danielle Gross, Matthew A. Nugent, György Hajnóczky, and Renato V. Iozzo^**

From the  Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, ^¶ LifeCell Corporation, Branchburg, New Jersey 08876,  Department of Biochemistry, Boston University School of Medicine, Boston, Massachusetts 02118, and ^** Cell Biology and Signaling Program, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107

Received for publication, June 27, 2000, and in revised form, July 19, 2000

	ABSTRACT

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

The small leucine-rich proteoglycan decorin interacts with the epidermal growth factor receptor (EGFR) and triggers a signaling cascade that leads to elevation of endogenous p21 and growth suppression. We demonstrate that decorin causes a sustained down-regulation of the EGFR. Upon stable expression of decorin, the EGFR number is reduced by ~40%, without changes in EGFR expression. However, EGFR phosphorylation is nearly completely abolished. Concurrently, decorin attenuates the EGFR-mediated mobilization of intracellular calcium and blocks the growth of tumor xenografts by down-regulating the EGFR kinase in vivo. Thus, decorin acts as an autocrine and paracrine regulator of tumor growth and could be utilized as an effective anti-cancer agent.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

The factors that control tumor progression in vivo involve, among others, the interplay between the invading neoplastic cells and the tumor stroma, a newly formed connective tissue highly enriched in proteoglycans, growth factors, and cytokines. Proteoglycans not only constitute a physical barrier to the invading tumor cells but also influence their behavior by binding and storing growth factors or by activating cell surface receptors (1, 2). Decorin, a prototype member of an expanding family of small leucine-rich proteoglycans, plays key roles in regulating matrix assembly and cell proliferation (3, 4). Most of decorin's biological interactions occur via the central leucine-rich repeat region, an arch-shaped structure whose concave surface is well suited to bind both globular and nonglobular proteins (5). Our working hypothesis is that the increased expression of decorin around invasive carcinomas represents a mechanism designed to counteract the invading neoplastic cells (6). This hypothesis is based on several observations. For instance, decorin levels are markedly elevated during growth arrest and quiescence, its expression is abrogated by viral transformation, and its transcription is suppressed in most tumorigenic cell lines (4). Upon transgenic expression of decorin, tumor cells with diverse histogenetic backgrounds revert to their normal phenotype; they loose anchorage-independent growth, fail to generate tumors in immunocompromised animals, and become arrested in G₁ (7, 8). Lack of decorin expression is permissive for tumor development insofar as bitransgenic mice lacking both decorin and the tumor suppressor p53 develop an accelerated lymphoma tumorigenesis (9). We discovered that decorin causes dimerization and autophosphorylation of the epidermal growth factor receptor (EGFR),¹ and that it binds both the soluble EGFR ectodomain and the immunopurified EGFR (10, 11). This interaction triggers a signal cascade leading to activation of mitogen-activated protein kinases (10), mobilization of intracellular calcium (12), up-regulation of p21^WAF1/CIP1 (p21), a potent inhibitor of cyclin-dependent kinases (13), and ultimately to growth suppression (7, 8, 14).

Despite the above findings, the mechanism by which decorin exerts its cytostatic effects is not understood. It is also unclear how activation of the EGFR by decorin would result in protracted growth suppression. In this investigation, we discovered that decorin leads to a profound and sustained down-regulation of the EGFR. Concurrently, decorin attenuates the EGFR-mediated mobilization of intracellular calcium and blocks the growth of tumor xenografts by acting as an in vivo paracrine growth inhibitor. These results provide an explanation for the long term effects of decorin on tumor suppression and suggest novel therapeutic approaches against cancer.

	EXPERIMENTAL PROCEDURES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Materials and Cell Cultures-- Media and fetal bovine serum were purchased from Mediatech (Herndon, VA). Hybond ECL membranes were purchased from Amersham Pharmacia Biotech, and AG1478 was purchased from Calbiochem. Antibodies include polyclonal rabbit antibodies against the N-terminal region of decorin (15) and monoclonal antibodies against human p21 (6B6; Pharmingen), against the human EGFR (Ab-12; NeoMarkers, Inc.), and against phosphotyrosine (PY20, Transduction Laboratories). Recombinant human decorin proteoglycan and decorin protein core were purified as before (16). ¹²⁵I-EGF was purchased from Amersham Pharmacia Biotech, and EGF was from R & D Systems. A431 squamous carcinoma cells were obtained from ATCC.

Stable Transfection and Northern and Western Immunoblotting-- Generation of A431 clones stably expressing decorin in pcDNA3.1 (Invitrogen) and screening procedures by Northern blotting were described before (8). Cells, rendered quiescent by serum deprivation for 24-36 h, were incubated with various ligands for 5-10 min, washed extensively, and processed for Western immunoblotting as described before (7, 8). The growth of various clones was monitored by CellTiter 96^TM, a nonradioactive cell proliferation assay (Promega). Fluorescence-activated cell sorting analysis was performed as described before (8).

Binding Studies with Iodinated EGF-- A431, AD13, AD14, and AD15 cells (5 × 10⁴ cells/2 cm²) were plated in complete medium (Dulbecco's modified Eagle's medium, 10% fetal bovine serum) into 24-well plates (Costar; Corning, NY). EGF binding was conducted with confluent cell cultures essentially as described previously (17). Briefly, cells were washed with ice-cold binding buffer (Dulbecco's modified Eagle's medium, 1 mg/ml bovine serum albumin, 25 mM Hepes, pH 7.2), and incubated for 10 min at 4 °C. ¹²⁵I-EGF was added directly to the binding buffer along with the appropriate amount of unlabeled EGF (0.01-50 ng/ml). A large excess (2 µg/ml) of unlabeled EGF was added to replicate wells in the presence of each concentration of ¹²⁵I-EGF to empirically determine nonspecific binding levels. Cells were incubated for 3 h at 4 °C and washed three times with cold binding buffer, and bound ¹²⁵I-EGF was extracted with 10 mM Tris, pH 7.4, 1 mM EDTA, 0.5% SDS for 15 min at room temperature. ¹²⁵I-EGF was quantified in a -counter (Packard Auto  5650). Nonspecific binding, generally <2% of the input radioactivity, was subtracted from each experimental value. Specific binding was determined by the method of Scatchard using a single site model to determine the K_d and number of EGF receptors per cell. While our data showed a somewhat curvilinear profile indicative of two classes of binding sites, the higher affinity class represented a very small percentage (<3%) of the total and could not be accurately resolved by our analysis. Thus, we applied a single-site linear regression analysis to the data, which yielded better fits with less statistical error.

Co-culture Experiments and Cytosolic [Ca²⁺] ([Ca²⁺]_c) Fluorescence Imaging-- A431 cells were cultured in 12-well culture plates (~10⁵ cells/well), while the decorin-expressing clones were cultured in microporous inserts (3 µm) and placed on the top of the A431 cells. After several days in co-culture, the target cells were tested for growth and EGFR phosphorylation as described above. For fluorescence imaging, the A431 cells and two of their decorin-expressing subclones, AD13 and AD14, were plated onto poly-D-lysine-coated coverglasses and grown to confluence in Dulbecco's modified Eagle's medium supplemented with 5% fetal calf serum and serum-starved for 24-36 h. The cells were loaded with the Ca²⁺-insensitive hydrophobic acetoxymethylester form of fura2 for 25-30 min at room temperature in an extracellular medium containing 121 mM NaCl, 5 mM NaHCO₃, 10 mM Na-HEPES, 4.7 mM KCl, 1.2 mM KH₂PO₄, 1.2 mM MgSO₄, 2 mM CaCl₂, 10 mM glucose, and 2% bovine serum albumin, pH 7.4, supplemented with 0.003% pluronic acid and sulfinpyrazone (200 µM). After loading with fura2/AM, cells were washed into an extracellular medium with 0.25% bovine serum albumin supplemented with sulfinpyrazone. Subsequently, the coverslips were mounted on the thermostated stage (35 °C) of an Olympus IX70 inverted epifluorescence microscope coupled to a high quantum efficiency cooled CCD camera driven by a customized computer program that also controlled a scanning monochromator (DeltaRAM, PTI) to select multiple excitation wavelengths (18). Fura2 fluorescence was measured at 340- and 380-nm excitation using a 400-nm long pass dichroic and a 510/80-nm band pass emission filter. At the end of each measurement, cells were permeabilized with an intracellular medium composed of 120 mM KCl, 10 mM NaCl, 1 mM KH₂PO₄, 20 mM Tris-Hepes, 2 mM MgATP, and 1 µg/ml each of antipain, leupeptin, and pepstatin, pH 7.2, supplemented with 40 µg/ml digitonin, and the fluorescence remaining in the cells was accounted as background fluorescence. Images of the background fluorescence were subtracted from the images collected from intact cells prior to calculation of the fluorescence ratios. To calculate [Ca²⁺]_c in nM, [Ca²⁺]_fura2 was calibrated in intracellular medium.

In Vivo Studies-- To test the ability of decorin to function as a tumor repressor in vivo, decorin-producing cells were co-injected with wild-type A431 human squamous carcinoma cells into 4-6-week-old male nu/nu mice (Taconic) and treated in accordance with institutional guidelines. AD13 cells (A431 cells stably transfected with the human decorin transgene) were mixed with A431 cells in 1:2, 1:4, or 1:8 ratios and injected either alone or in the various combinations described in the text (see Fig. 7 legend). Mice were carefully examined every two or three days for up to 35 days postinjection, and any tumor growth was measured with a microcaliper using the formula V = a(b²/2), where a is the width at the widest point and b is the width perpendicular to a. Tumors were frozen in liquid nitrogen, pulverized in a mortar, and boiled in SDS-polyacrylamide gel electrophoresis buffer containing 100 mM -mercaptoethanol before processing for SDS-PAGE and Western immunoblotting. Parallel samples were analyzed by conventional light microscopy (9).

	RESULTS

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

De Novo Decorin Expression Causes Growth Suppression and Sustained Down-regulation of the EGFR-- Transmission of extracellular signals often starts with binding of a growth factor to surface receptors that in many cases carry an intrinsic tyrosine kinase activity (19, 20). For example, EGF stimulates the formation of homo- and heterodimers with other members of the family of receptor tyrosine kinase, a process that generally leads to growth stimulation (21). However, the proliferation of tumor cells bearing high levels of EGFR, such as A431 squamous (22) or MDA468 mammary (23) carcinoma cells, is stimulated by picomolar but paradoxically suppressed by nanomolar concentrations of EGF, presumably via down-regulation of the EGFR (24). To investigate whether decorin might induce growth suppression by activating a similar pathway, we established a number of A431 clones expressing the full-length human decorin driven by the potent cytomegalovirus promoter. All of the decorin-expressing clones (Fig. 1, A and B) exhibited increased levels of endogenous p21 (Fig. 1C) and became growth-retarded (Fig. 1D), with a proportional increase in cells arrested in G₁ (Fig. 1E). The addition of either recombinant decorin or decorin protein core (1 µM) caused growth inhibition in wild-type A431 cells, an effect mediated by the EGFR insofar as AG1478 (1 µM), a tyrphostin that specifically inhibits the EGFR kinase (25), abrogated the cytostatic effects induced by either decorin or EGF (not shown).

View larger version (30K): [in this window] [in a new window]   Fig. 1.   Ectopic expression of decorin causes growth suppression in A431 squamous carcinoma cells via the EGFR. A, survey by Northern blotting of A431 cells stably transfected with full-length human decorin following hybridization with either decorin or GAPDH cDNAs as indicated. Three clones expressing the highest amounts of decorin (AD13, AD14, and AD15 corresponding to lanes 2, 12, and 13, respectively) were studied in detail. B, immunoblotting of media conditioned by either A431 or decorin-expressing clones with an antibody directed against the N-terminal region of decorin. C, immunoblotting of cell lysates from either A431 or decorin-expressing clones as indicated using a monoclonal antibody against human p21. D, growth curves of A431 and decorin-expressing clones. The number of proliferating cells was determined using a tetrazolium/formazan assay. Each point represents the mean ± S.D. (n = 5). E, proportion of cells in the G1 phase of the cell cycle as determined by fluorescence-activated cell sorting analysis. Values represent the mean ± S.D. (n = 4).

Three decorin-expressing clones (AD13, AD14, and AD15) were studied in depth. While the steady state levels of EGFR declined by ~40% (42 ± 8%, n = 5), the degree of EGFR activation, as measured by its phosphorylation status, declined by ~95% (Fig. 2, A and B). When the blots were exposed for a short time (2 s), there was no detectable EGFR phosphorylation in the decorin-expressing clones. Only when the blots were saturated (after a 6-s exposure) could tyrosyl phosphorylation of the EGFR be detected (Fig. 2A). The involvement of a nonspecific phosphatase was ruled out by experiments in which even relatively high concentrations of Na₃VO₄ (100 µM) caused no significant change in the state of EGFR phosphorylation (not shown). Moreover, the steady state levels of EGFR mRNA were not significantly altered in the decorin-expressing clones (Fig. 2C), although there was clonal variability in EGFR expression.

View larger version (56K): [in this window] [in a new window]   Fig. 2.   Decorin causes a sustained down-regulation of the EGFR, but the remaining EGFRs respond similarly to EGF challenge. A, steady state levels of EGFR and its tyrosyl phosphorylation as determined by Western immunoblotting with antibody against EGFR or phosphotyrosine as indicated. Equal amounts of proteins (50 µg/lane) from quiescent and serum-deprived cells were used. B, quantification by scanning densitometry of the degree of tyrosyl phosphorylation of the EGFR. C, Northern blotting analysis of EGFR mRNA steady state levels. RNA was isolated from ~107 confluent cells following a 24-h serum starvation and probed with a polymerase chain reaction-generated 726-base pair fragment encompassing the 3'-end of EGFR (base pairs 3112-3837). Notice the presence of an ~10-kilobase pair band corresponding to the major transcript of EGFR. A second band of ~5.5 kilobase pairs could be detected after longer exposure (12 h). The Northern blotting was exposed for 30 min. The apparent higher levels of EGFR message in AD14 and AD15 could not be reproduced in a separate experiment, and it might be due to loading differences. The asterisks correspond to the migration of rRNA shown in the lower panel. D, Scatchard plot for the binding of 125I-labeled EGF to A431 and its decorin-expressing clones as indicated to determine the Kd and number of EGF receptors per cell. Each value represents the mean ± S.D. (n = 3). Equilibrium binding was normalized to 1.75 × 106 cells. The Kd values were 19 ± 4, 21 ± 4, 18 ± 4, and 15 ± 5 nM for A431, AD13, AD14, and AD15 cells respectively. The numbers of binding sites were 2.4 ± 0.1, 1.5 ± 0.1, 1.1 ± 0.1, and 1.2 ± 0.1 × 106 sites per cell for A431, AD13, AD14, and AD15 cells, respectively. These experiments were repeated five times with comparable results. E, Western immunoblotting of total cell lysates (50 µg/lane) following a 10-min challenge with EGF at the indicated concentrations. The blots were sequentially reacted with anti-EGFR or phosphotyrosine antibodies as indicated. F, quantification by scanning densitometry of the degree of tyrosyl phosphorylation of the EGFR normalized on EGFR levels. The values represent the mean of duplicate determinations from several autoradiograms exposed in the linear range.

When ¹²⁵I-EGF binding was conducted, the number of binding sites/cell was reduced in all of the decorin-expressing clones to levels comparable with those obtained with immunoblotting (Fig. 2D). Specifically, the binding sites/cell were 2.4 × 10⁶ in A431 cells, in contrast to the AD13, AD14, and AD15, which expressed 1.5, 1.1, and 1.2 × 10⁶ binding sites/cell, respectively. Interestingly, the affinity constants determined by Scatchard analysis were not significantly different among the various cell lines (K_d = 15-21 nM). These experiments were repeated five times with comparable results.

To further prove that the affinity of the EGFR for EGF was not significantly affected by decorin, quiescent cells were exposed for 10 min to various concentrations of EGF. In agreement with the data presented above, the decorin-expressing cells showed reduced levels of EGFR protein (Fig. 2E, upper panel) and, in the absence of exogenous EGF, displayed no detectable EGFR phosphorylation (Fig. 2E, lower panel). However, the activation of the remaining EGFRs was not markedly altered. When the blots were quantified by scanning densitometry, the degree of EGFR phosphorylation upon EGF challenge followed a pattern similar to the controls (Fig. 2F) although somewhat attenuated at submaximal (10 ng/ml) concentrations of EGF. Similar results were obtained with a 5-min exposure to EGF (not shown).

Thus, decorin induces a substantial reduction in the number of EGFRs without affecting EGFR mRNA steady-state levels. However, decorin causes an even greater suppression of EGFR phosphorylation.

Decorin Does Not Affect the Rate of EGFR Dephosphorylation following EGF Challenge-- A potential mechanism for the down-regulation of EGFR includes an increased rate of intracellular dephosphorylation after ligand activation (19, 24, 26). To address this issue, we exposed quiescent (incubated in serum-free medium for 24 h) A431 or AD13 cells to EGF (40 ng/ml) for 5 min and then chased the cells for 1-40 min in the same medium supplemented with or without AG1478 (2 µM) to block EGFR kinase. While the control samples, treated with Me₂SO vector alone, showed no appreciable EGFR dephosphorylation within the 40-min chase, the AG1478-treated samples showed a very rapid disappearance of EGFR tyrosyl phosphorylation (Fig. 3A). Although quantitatively different, the half-life of EGFR tyrosyl phosphorylation was essentially the same in both A431 and AD13 cells, t_1/2 ~ 40 ± 10 s (Fig. 3B). Notably, the EGF-induced tyrosyl phosphorylation of c-Cbl and the 85-kDa subunit of phosphatidylinositol 3-kinase, both known to be substrates for EGFR kinase, decayed even faster than EGFR (Fig. 3A). Because in these experiments the medium was not changed before adding EGF or AG1478, we conclude that the accumulated decorin synthesized in 24-25 h does not significantly affect the rate of EGFR dephosphorylation following ligand-induced phosphorylation of the EGFR.

View larger version (49K): [in this window] [in a new window]   Fig. 3.   Decorin does not affect the rate of intracellular EGFR dephosphorylation. A, Western immunoblotting of total cell lysates probed with anti-phosphotyrosine antibodies following a 5-min incubation with EGF (40 ng/ml) and continuous incubation for the designated time intervals in the same medium supplemented with either 0.25% Me2SO alone or containing 2 µM AG1478 to block EGFR tyrosine kinase. In these experiments, which were repeated two times with identical results, the medium was not changed so that decorin accumulated in the medium of the AD13 cells in the 24 h before the commencement of the experiment and was present throughout the incubation. B, quantification of the rate of EGFR tyrosyl phosphorylation following incubation with AG1478 for the indicated times. The values are the mean ± S.D. of triplicate values.

Decorin Acts as a Paracrine Suppressor of EGFR Kinase Activity-- A potential problem in interpreting data from stably transfected cells is the plausible integration of the transgene into a locus that may inadvertently activate or suppress a gene involved in the EGFR signaling pathway. To address this issue, we established co-culture experiments in which either A431 or the decorin-secreting clones (AD13, AD14, or AD15) were cultured in the top chamber of a microporous (3-µm diameter) well, while the bottom wells contained A431 cells. Thus, any soluble molecules, but not cells, would be able to diffuse through the membrane and affect the behavior of the target A431 cells. After 5 days in culture in complete medium containing 10% serum, there was a significant inhibition of A431 cell growth only when the cells were co-cultured in the presence of the decorin-expressing clones at various ratios (Fig. 4, A and B). Concurrent with these changes, there was a marked suppression of EGFR tyrosyl phosphorylation (Fig. 4, C and D). In a time course experiment, decorin-mediated EGFR phosphorylation peaked at ~ 2 h and declined to very low levels at 6-8 h (not shown).

View larger version (28K): [in this window] [in a new window]   Fig. 4.   Decorin acts as a paracrine inhibitor of cell growth and suppresses EGFR kinase activity in co-culture experiments. A, growth of A431 cells co-cultured for 5 days in the presence of either A431 or decorin-expressing clones, as indicated, at a 1:6 ratio. The values represent the mean ± S.D. (n = 3) of duplicate experiments. B, similar experiment to A, with the exception that co-cultures were grown at a 1:9 ratio. C, degree of tyrosyl phosphorylation of the EGFR as determined by immunoblotting with -Tyr(P) antibodies (PTyr). D, degree of EGFR phosphorylation as determined by scanning densitometry of gels similar to those shown in C and normalized on EGFR levels. The values represent the mean ± S.D. from several autoradiograms exposed in the linear range.

Collectively, these results indicate that secreted decorin can induce the same biochemical changes as the endogenous transgene and demonstrate a role for decorin as a paracrine regulator of tumor cell growth and EGFR kinase activity.

Cytosolic [Ca²⁺] Signal Induced by EGF Is Attenuated in the Decorin-expressing Cells-- One of the downstream effectors of the EGFR is phospholipase C that binds through its SH2 domains to the activated EGFR and becomes tyrosine-phosphorylated. Phospholipase C catalyzes the formation of inositol 1,4,5-triphosphate that in turn mobilizes Ca²⁺ from internal stores, leading to elevations of [Ca²⁺]_c, a signal that plays fundamental roles in the control of cellular growth and differentiation (27, 28). It has also been shown that down-regulation of EGFR results in attenuated EGF-activated [Ca²⁺]_c signals (12, 29).

To test if the EGFR-linked [Ca²⁺]_c signaling could be involved in the changes in expression and phosphorylation of the EGFR described above, we monitored [Ca²⁺]_c in intact, individual cells loaded with the ratiometric fluorescent Ca²⁺ indicator fura2 (18). The resting [Ca²⁺]_c did not vary between the wild-type and decorin-expressing cells (48 ± 11 nM in A431, 44 ± 5 nM in AD13, and 49 ± 5 nM in AD14 cells, respectively). The addition of a maximal dose of EGF (100 ng/ml) to A431 cells evoked a large [Ca²⁺]_c increase essentially in every cell (green-red shift, images i-iii in Fig. 5A), and the [Ca²⁺]_c signal displayed a rapid upstroke followed by a slow decay (Fig. 5A, panel iv). In contrast, the decorin-expressing clones showed either no elevation or a slow and small elevation of [Ca²⁺]_c (images i-iii in Fig. 5, B and C). Time course traces of the mean [Ca²⁺]_c changes in AD13 and AD14 cells also showed the attenuated [Ca²⁺]_c signal in response to maximal EGF (Fig. 5, A-C, panels iv).

View larger version (73K): [in this window] [in a new window]   Fig. 5.   Imaging of [Ca2+]c signals induced by a saturating dose of EGF in wild type and decorin-expressing A431 cells. Cytosolic [Ca2+] was monitored in individual cells using the ratiometric fluorescent Ca2+ indicator fura2. Binding of Ca2+ to fura2 yields an increase in the fluorescence when excited at 340 nm (shown in red) and a decrease when excited at 380 nm (green). The images of fura2-loaded A431 (A), AD13 (B), and AD14 (C) collected before (i images) and after (+30 and +90 s, ii and iii images) the addition of EGF are shown as overlays of the 340- and 380-nm images. The mean time course traces of [Ca2+]c recorded in individual cells are shown as the fluorescence ratio of fura2 normalized to the base line (iv). Data are representative of four independent experiments.

To further investigate the mechanisms underlying the impaired [Ca²⁺]_c signaling in the decorin-expressing cells, we monitored the [Ca²⁺]_c responses evoked by submaximal and maximal doses of EGF and by ATP that elicits Ca²⁺ mobilization without activation of EGFR or phospholipase C. A suboptimal dose of EGF (10 ng/ml) elicited [Ca²⁺]_c elevations that were 70 ± 11 and 58 ± 16% smaller in AD13 and AD14 cells, respectively, than A431 cells (n = 6, p < 0.05 for both, Fig. 6). The extent of suppression of the elevations evoked by maximal EGF (100 ng/ml) was 50 ± 14 and 66 ± 10% in AD13 and AD14 cells, respectively (n = 4, p < 0.02 and <0.01, respectively). In contrast, ATP (200 µM) evoked [Ca²⁺]_c increases that were not significantly different in the wild-type and decorin-expressing clones (AD13, 87 ± 18%; AD14, 129 ± 19% of A431; n = 10).

View larger version (27K): [in this window] [in a new window]   Fig. 6.   Comparison of EGF- and ATP-induced [Ca2+]c signals in wild type and decorin-expressing A431 cells. Experiments were carried out as described in Fig. 5. A, average time course traces calculated from 4-7 separate measurements are shown (see numbers on the graphs). In each measurement, [Ca2+]c responses given by 30-50 individual cells were averaged. A431, AD13, and AD14 cells were challenged with a submaximal (10 ng/ml, left) or a maximal (100 ng/ml, right) dose of EGF. Subsequently, the cells were challenged with ATP (200 µM). B, bar graphs showing the magnitude of the[Ca2+]c responses evoked by 10 ng/ml EGF (left), 100 ng/ml EGF (middle), and 200 µM ATP (right).

These data show impairment of the EGF-activated calcium signaling pathway in the decorin-expressing cells. Because no attenuation of the ATP-induced calcium signals was found in the decorin-expressing cells, changes in the EGFR or a factor proximal to inositol 1,4,5-triphosphate formation should account for the abnormal EGF-activated calcium signaling.

In Vivo Abrogation of Tumor Growth by Decorin-- To test whether decorin could act as an autocrine and paracrine inhibitor of in vivo tumor growth, A431 or AD13 cells were injected into nude mice either alone or in various combinations. Notably, the decorin-expressing AD13 cells did not form any tumors (Fig. 7A) even after 3 months of observation following the end point of the experiment. In contrast, the A431 cells and the 1:2 ratio generated tumors essentially with similar kinetics. However, the 1:4 and 1:8 tumors were significantly smaller than controls after 4 weeks of xenograft growth. In a second set of experiments (Fig. 7B), we utilized ratios in which the number of co-injected tumor cells was kept proportional to the wild-type cells. The A431-injected mice (0.25 and 1.0 × 10⁶ cells) exhibited identical rates of tumor growth and are shown as a single line (Fig. 7B). At no time did the 1:4 (0.25; 1.0 × 10⁶ A431/AD13 cells), the 1:8 (0.25; 2.0 × 10⁶ A431/AD13 cells) mixtures or the AD13-injected mice show any tumor growth. These animals were allowed to live for an additional 3 months with no signs of tumor.

View larger version (49K): [in this window] [in a new window]   Fig. 7.   Decorin acts as an autocrine and paracrine inhibitor of tumor growth in vivo. A, growth of tumor xenografts in nude mice, following injection of A431 or AD13 cells alone or in combination as indicated. In these experiments, the number of the cells was not kept constant. A431 and AD13 alone were injected at 1 × 106 cells/animal. The 1:2 ratio animals received 1 × 106 A431 and 2 × 106 AD13, whereas the 1:4 and 1:8 ratio animals were injected with 0.25 × 106 A431 and 1 × 106 AD13, or 0.2 × 106 A431 and 1 × 106 AD13, respectively. Each point represents the mean ± S.E. (n = 5). B, in these experiments, the number of A431 cells was kept constant at 0.25 × 106/animal in the co-injection. Wild-type A431 cells (n = 9) include animals injected with either 0.25 × 106 or 1 × 106 cells, and the results are pooled as the groups grew identically. The values represent the mean ± S.E. (n = 3 for each group except for A431 controls, where n = 9). C, morphology of the tumors from A. Notice the invasion of skeletal muscle (i) and prominent tumor angiogenesis (ii). In contrast, the co-injected tumors show no invasion of the subcutaneous structures (iii) and evidence of cytodifferentiation with tumor cells growing as islands surrounded by a collagenous matrix (iv) and showing evidence of polarization (v) and abundant deposition of cytokeratin (vi). D, Coomassie-stained SDS-polyacrylamide gel electrophoresis of pooled triplicates (60 µg/lane) from tumor cell lysates as indicated. The molecular mass in kDa of prestained size markers is indicated on the left. E, Western immunoblotting of samples identical to D using anti-phosphotyrosine antibodies. Note the reduction of tyrosyl phosphorylation of the EGFR in the 1:4 and 1:8 co-injected tumor xenografts.

All of the A431-generated tumor xenografts revealed extensive invasion of the deep fascia and subcutaneous skeletal muscles (Fig. 7C, i), together with copious neovascularization (Fig. 7C, ii). In contrast, the 1:4 ratio showed very sharp margins and no infiltration of the deeper soft tissues (Fig. 7C, iii). In addition, the 1:8 ratio revealed evidence of cytodifferentiation characterized by the formation of tumor nests surrounded by a dense collagenous matrix (Fig. 7C, iv), polarized epithelial cells (Fig. 7C, v), and extensive keratin formation (Fig. 7C, vi). Western immunoblotting of pooled tumor cell lysates from three xenografts revealed that at similar protein concentration (Fig. 7D) there was a significant down-regulation of EGFR phosphorylation in the 1:4 and 1:8 xenografts (Fig. 7E). However, no human decorin was detected in the tumor xenografts using sensitive immunoblotting assays and purified decorin as positive controls (not shown). We estimated that the decorin levels in the 1:4 and 1:8 tumor xenografts were 10 ng/50 µg of total cell protein. This is probably due to the poor survival of the decorin-expressing cells, since the AD13 alone never generated tumors in several independent experiments using different tumor cell inocula. Thus, the initial exposure to decorin might have been sufficient to down-regulate the EGFR for a protracted time in the A431 cells.

These data substantiate the co-culture experiments described above and further demonstrate that tumor cells genetically engineered ex vivo to express decorin can suppress the growth of EGFR-overexpressing tumor cells in both a paracrine and autocrine fashion.

	DISCUSSION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Overexpression of ErbB receptor tyrosine kinase correlates with poor prognosis in a wide variety of human cancers (20). We find that exposure of A431 carcinoma cells to a soluble leucine-rich proteoglycan causes a sustained down-regulation of the EGFR. The fact that decorin has no homology with EGF is not surprising, since EGFR is promiscuous and encompasses integration of stimuli as diverse as ultraviolet irradiation (30), G protein-coupled serpentine receptors (31), voltage-sensitive calcium channels (32), growth hormone (33), and interleukin-6 (34). On this basis, the EGFR can be considered as a prototype switch point for multiple environmental and internal stimuli (24). Our findings extend these observations and identify decorin as a powerful and long acting biological substance capable of controlling tumor growth by desensitizing the EGFR. Whereas the amount of EGFR and the number of EGF-binding sites decline by 40-50%, the degree of EGFR tyrosyl phosphorylation is nearly totally abrogated, and the mobilization of intracellular calcium stores, a key EGFR-mediated signaling pathway, is markedly attenuated by decorin. Interestingly, the intracellular dephosphorylation rate of EGFR is not appreciably changed by decorin. Tumor xenografts formed by co-injection of A431 cells and their decorin-expressing counterparts grow more slowly or not at all. This is probably due to a paracrine action of decorin, a mechanism corroborated by co-culture experiments. The action of decorin is reminiscent of herceptin, a humanized monoclonal antibody directed against the extracellular domain of ErbB2 (35). Herceptin treatment of ErbB2-overexpressing mammary tumor cells causes suppression of ErbB2 and a concurrent induction of the cyclin-dependent kinase inhibitor p27^KIPI and the retinoblastoma-related protein p130, both of which prevent the cells from traversing the S phase (35). Using ErbB2-overexpressing mammary tumor cells, we have recently discovered that decorin also causes suppression of ErbB2 phosphorylation and growth by inducing p21 and cytodifferentiation (44). Thus, decorin appears to act as a ligand that suppresses the kinase activity of various ErbB members and ultimately leads to cytostasis.

Extracellular Matrix Proteins Interact with Receptor Tyrosine Kinase-- The unexpected realization that extracellular matrix molecules can directly serve as ligands for receptor tyrosine kinases has changed the prevailing views about the mechanisms by which cells perceive and respond to extracellular signals (4). The discovery that discoidin domain receptors 1 and 2, two orphan receptor tyrosine kinases, are the receptors for fibrillar collagen opens new perspective in understanding how matrix molecules affect cell behavior (36, 37). Activation of the discoidin domain receptor kinase requires the native triple helix of collagen, and this interaction differs from typical growth factor/receptor signaling insofar as the kinetics of activation are much slower and protracted in time, similar to the decorin/EGFR interplay. Collagen-induced activation of discoidin domain receptor 2 causes enhanced collagenase (MMP-1) expression, thereby leading to a negative feedback loop that would control the extracellular levels of collagen (36). Because decorin is intimately associated with fibrillar collagen, a complex scenario where multimeric interactions might take place should be contemplated. Specificity would occur at the cellular level, since the expression of EGFR and discoidin domain receptors are quite distinct. An increase in decorin content in the newly formed tumor stroma could trigger a functional interaction with the EGFR, known to be highly expressed in many tumor cells, thereby initiating a signaling cascade that would directly block the cell cycle.

Mechanisms of EGFR Inhibition by Decorin-- Apart from differential recruitment of tyrosine phosphatases or the negative c-Cbl, endocytosis of ligand-receptor complexes is a major mechanism for the gradual attenuation of growth factor signaling (38, 39). Endocytosis of the EGFR requires activation of its intrinsic tyrosine kinase and autophosphorylation (29), both of which are induced by decorin (10, 11). Decorin may lead to deactivation of the EGFR signaling by various plausible mechanisms. First, it might bring to the vicinity of the EGFR a transmembrane tyrosine phosphatase. We do not favor this mechanism, since high concentrations of the phosphatase inhibitor Na₃VO₄ did not alter the degree of EGFR phosphorylation. Second, decorin might activate a cell surface protein that would in turn bind the EGFR, thereby preventing homo- or heterodimerization and ultimately suppressing its phosphorylation. Our previous results, however, suggest that decorin might bind directly to EGFR and activate the EGFR kinase both in vivo and in a cell-free environment (10, 11). Third, decorin could mask the accessibility of the EGFR ectodomain to various ligands, such as transforming growth factor-, a known EGFR activator and autocrine regulator of growth produced by most tumorigenic cells (21). Fourth, decorin might cause a protracted engagement of the EGFR, either directly or indirectly through other ErbB members, leading to receptor down-regulation through a sustained endocytosis and intracellular degradation pathway. This could cause a suppression of the available EGFRs at the cell surface, thus preventing activation of the receptor pool. We favor this possibility because reduction in EGFR protein and EGF-binding sites did not correlate with reduced EGFR mRNA levels. Thus, a post-transcriptional mechanism must be operational to cause a physical down-regulation of the EGFR protein and its kinase activity. It is known that at relatively high EGFR levels (1-2 × 10⁶/cell), such as in A431 and breast cancer cells (23), the formation of high affinity EGFR dimers occurs even in the absence of the ligand and that attachment of a specific ligand stabilizes the dimer complex that otherwise might dissociate into its monomeric (inactive) elements (26). The shift caused by decorin may generate an imbalance between the constitutively active EGFR kinase of dimers and their counteracting phosphotyrosine phosphatases. This mechanism might be sufficient to explain the decline in EGFR activity.

Genetic Evidence from Drosophila for the Presence of Leucine-rich Proteins Blocking the EGFR-- Strong support for a biological function of mammalian decorin as a blocker of EGFR activity derives from the discovery of EGFR antagonists in Drosophila. A major function of Drosophila EGFR is to induce a dorsal fate in the follicle cells that surround the oocyte and secrete eggshell (40, 41). Kekkon1, a transmembrane protein that contains six leucine-rich repeats homologous to decorin, accumulates in the dorsal-anterior follicle cells in an EGFR-dependent manner (42, 43). Overexpression of Kekkon1 blocks the formation of dorsal appendages, thus identifying Kekkon1 as a negative regulator of EGFR signaling (42). The activity of Kekkon1 can be overcome by co-expression of an activated EGFR or downstream effectors, but not by molecules, such as rhomboid, that enhance ligand-induced activation of the EGFR (41). Like decorin, Kekkon1 associates with the EGFR, a function that requires the extracellular leucine-rich domain but not its intracellular domain (42). Although the mechanism of action of Kekkon1 appears to differ from that of decorin, the end result is common, i.e. a block of the EGFR-transducing pathway. Thus, the leucine-rich repeats of Kekkon1 and decorin may represent an evolutionarily preserved mechanism by which cells control signaling via the EGFR. While Kekkon1, being a transmembrane protein, would interact primarily with adjacent EGFRs on the same cells, decorin, being a secreted protein, could diffuse distantly and interact with a number of cells expressing various levels of EGFR. Thus, decorin opens the possibility of novel therapeutic approaches in cancer by delivering a natural inhibitor of the EGFR signaling pathway. This would represent an advantage over conventional gene therapies, which generally affect only the cells that have been successfully transduced. A single decorin-transfected cell could conceivably affect several neighboring cells, rendering decorin-mediated growth suppression effective even in systems with low or unpredictable transfection rates.

	ACKNOWLEDGEMENT

We thank L. Fisher (National Institutes of Health) for providing valuable antibodies.

	FOOTNOTES

^* This work was supported by National Institutes of Health Grants CA39481 and CA47282 (to R. V. I.), EY11004 (to M. A. N.), and DK51526 (to G. H) and by a Burroughs Wellcome Fund Career Award in the Biomedical Sciences (to G. H).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

^§ These two authors contributed equally to this work.

To whom correspondence should be addressed: Dept. of Pathology, Anatomy and Cell Biology, Rm. 249, JAH, Thomas Jefferson University, 1020 Locust St., Philadelphia, Pennsylvania 19107. Tel.: 215-503-2208; Fax: 215-923-7969; E-mail: iozzo@lac.jci.tju.edu.

Published, JBC Papers in Press, July 25, 2000, DOI 10.1074/jbc.M005609200

	ABBREVIATIONS

The abbreviations used are: EGFR, epidermal growth factor receptor; EGF, epidermal growth factor; p21, the cyclin-dependent kinase inhibitor p21 ^WAF1/CIP1; [Ca²⁺]_c, cytosolic [Ca²⁺].

	REFERENCES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				D. Iacob, J. Cai, M. Tsonis, A. Babwah, C. Chakraborty, R. N. Bhattacharjee, and P. K. Lala Decorin-Mediated Inhibition of Proliferation and Migration of the Human Trophoblast via Different Tyrosine Kinase Receptors Endocrinology, December 1, 2008; 149(12): 6187 - 6197. [Abstract] [Full Text] [PDF]

				S. Goldoni, D. G. Seidler, J. Heath, M. Fassan, R. Baffa, M. L. Thakur, R. T. Owens, D. J. McQuillan, and R. V. Iozzo An Antimetastatic Role for Decorin in Breast Cancer Am. J. Pathol., September 1, 2008; 173(3): 844 - 855. [Abstract] [Full Text] [PDF]

				L. Schaefer and R. V. Iozzo Biological Functions of the Small Leucine-rich Proteoglycans: From Genetics to Signal Transduction J. Biol. Chem., August 1, 2008; 283(31): 21305 - 21309. [Abstract] [Full Text] [PDF]

				X. Bi, C. Tong, A. Dockendorff, L. Bancroft, L. Gallagher, G. Guzman, R. V. Iozzo, L. H. Augenlicht, and W. Yang Genetic deficiency of decorin causes intestinal tumor formation through disruption of intestinal cell maturation Carcinogenesis, July 1, 2008; 29(7): 1435 - 1440. [Abstract] [Full Text] [PDF]

				X. Li, A. Pennisi, and S. Yaccoby Role of decorin in the antimyeloma effects of osteoblasts Blood, July 1, 2008; 112(1): 159 - 168. [Abstract] [Full Text] [PDF]